<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="jcmm15364-tbl-0002" xml:lang="en" content-type="Table" orientation="portrait" position="float">
 <label>Table 2</label>
 <caption>
  <p>Potential antiviral drugs against COVID‐19</p>
 </caption>
 <table frame="hsides" rules="groups">
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <thead valign="top">
   <tr style="border-bottom:solid 1px #000000">
    <th align="left" valign="top" rowspan="1" colspan="1">Drug</th>
    <th align="left" valign="top" rowspan="1" colspan="1">Antiviral mechanism</th>
    <th align="left" valign="top" rowspan="1" colspan="1">References</th>
    <th align="left" valign="top" rowspan="1" colspan="1">Evidences</th>
    <th align="left" valign="top" rowspan="1" colspan="1">Therapeutic effect</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left" rowspan="2" colspan="1">Lopinavir/Ritonavir</td>
    <td align="left" rowspan="3" colspan="1">Viral protease inhibitors</td>
    <td align="left" rowspan="1" colspan="1">Kim et al 2020</td>
    <td align="left" rowspan="1" colspan="1">Clinical case study</td>
    <td align="left" rowspan="1" colspan="1">Did not decease the viral load and have gastrointestinal side effect</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Cao et al 2020</td>
    <td align="left" rowspan="1" colspan="1">Clinical trial</td>
    <td align="left" rowspan="1" colspan="1">No benefit was observed in hospitalized adult patients with severe Covid‐19</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Disulfiram</td>
    <td align="left" rowspan="1" colspan="1">Li and De Clercq 2020</td>
    <td align="left" rowspan="1" colspan="1">In vitro</td>
    <td align="left" rowspan="1" colspan="1">Has inhibitory activity against SARS and MERS</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Favipiravir</td>
    <td align="left" rowspan="6" colspan="1">Viral nucleoside analogs</td>
    <td align="left" rowspan="1" colspan="1">Wang et al 2020</td>
    <td align="left" rowspan="1" colspan="1">In vitro</td>
    <td align="left" rowspan="1" colspan="1">Favipiravir could suppress SARS‐COV‐2 infection at a high concentration</td>
   </tr>
   <tr>
    <td align="left" rowspan="4" colspan="1">Remdesivir</td>
    <td align="left" rowspan="1" colspan="1">Holshue et al 2020</td>
    <td align="left" rowspan="1" colspan="1">Clinical case study</td>
    <td align="left" rowspan="1" colspan="1">Cure a COVID‐19 patient in the United States by intravenous injection</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Wang et al 2020</td>
    <td align="left" rowspan="1" colspan="1">In vitro</td>
    <td align="left" rowspan="1" colspan="1">Remdesivir could block SARS‐CoV‐2 enter Vero E6 cells</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Gao et al 2020</td>
    <td align="left" rowspan="1" colspan="1">In vitro</td>
    <td align="left" rowspan="1" colspan="1">Revealed the possible inhibition mechanism of SARS‐COV‐2 RNA polymerase by Remdesivir effector molecules</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Grein et al 2020</td>
    <td align="left" rowspan="1" colspan="1">Clinical trial</td>
    <td align="left" rowspan="1" colspan="1">Remdesivir is effective in treating severe COVID‐19.</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Ribavirin and Galidesivir</td>
    <td align="left" rowspan="1" colspan="1">Li and De Clercq 2020</td>
    <td align="left" rowspan="1" colspan="1">No evidence</td>
    <td align="left" rowspan="1" colspan="1">Have therapeutic effect on patients with SARS and MERS but lacking the evidence for SARS‐COV‐2</td>
   </tr>
   <tr>
    <td align="left" rowspan="2" colspan="1">Chloroquine</td>
    <td align="left" rowspan="9" colspan="1">Virus‐host fusion inhibitors</td>
    <td align="left" rowspan="1" colspan="1">Wang et al 2020</td>
    <td align="left" rowspan="1" colspan="1">In vitro</td>
    <td align="left" rowspan="1" colspan="1">Suppression of COVID‐19 pneumonia exacerbation, reduction of symptom duration,</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Gao et al 2020</td>
    <td align="left" rowspan="1" colspan="1">Clinical trial</td>
    <td align="left" rowspan="1" colspan="1">Have apparent efficacy and acceptable safety against COVID‐19‐associated pneumonia in multicentre clinical trials conducted in China.</td>
   </tr>
   <tr>
    <td align="left" rowspan="2" colspan="1">Hydroxychloroquine</td>
    <td align="left" rowspan="1" colspan="1">Wang et al 2020</td>
    <td align="left" rowspan="1" colspan="1">In vitro</td>
    <td align="left" rowspan="1" colspan="1">Have the same antiviral mechanism with chloroquine</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Gautret et al 2020</td>
    <td align="left" rowspan="1" colspan="1">Clinical trial</td>
    <td align="left" rowspan="1" colspan="1">Hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID‐19 patients and its effect is reinforced by azithromycin.</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Arbidol</td>
    <td align="left" rowspan="1" colspan="1">Dong et al 2020</td>
    <td align="left" rowspan="1" colspan="1">In vitro</td>
    <td align="left" rowspan="1" colspan="1">Arbidol can effectively inhibit SARS‐CoV‐2 infection at a concentration of 10‐30 µM</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Nitazoxanide</td>
    <td align="left" rowspan="1" colspan="1">Wang et al 2020</td>
    <td align="left" rowspan="1" colspan="1">In vitro</td>
    <td align="left" rowspan="1" colspan="1">Have inhibition activity of the SARS‐COV‐2</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">IDX‐184</td>
    <td align="left" rowspan="1" colspan="1">Elfiky 2020</td>
    <td align="left" rowspan="1" colspan="1">In vitro</td>
    <td align="left" rowspan="1" colspan="1">Have effective against SARS‐CoV‐2 strain.</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Sofosbuvir</td>
    <td align="left" rowspan="1" colspan="1">Elfiky 2020</td>
    <td align="left" rowspan="1" colspan="1">In vitro</td>
    <td align="left" rowspan="1" colspan="1">Tightly combine with SARS‐CoV‐2 RdRp for viral clearance</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Corticosteroids</td>
    <td align="left" rowspan="1" colspan="1">Zhou and Liu 2020</td>
    <td align="left" rowspan="1" colspan="1">Clinical experience</td>
    <td align="left" rowspan="1" colspan="1">Low‐dose corticosteroids may be beneficial for the survival of severe COVID‐19 patients</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Baricitinib</td>
    <td align="left" rowspan="1" colspan="1">JAK signalling pathway inhibitor</td>
    <td align="left" rowspan="1" colspan="1">Richardson and Griffin 2020</td>
    <td align="left" rowspan="1" colspan="1">Benevolent AI‐derived knowledge graph</td>
    <td align="left" rowspan="1" colspan="1">Baricitinib could also abate SARS‐COV‐2 virus infectivity</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Traditional Chinese medicine</td>
    <td align="left" rowspan="1" colspan="1">Antiviral, anti‐immune/inflammatory and hypoxic reactions</td>
    <td align="left" rowspan="1" colspan="1">Zhang et al 2020</td>
    <td align="left" rowspan="1" colspan="1">In vitro evidence and clinical experience</td>
    <td align="left" rowspan="1" colspan="1">May also directly inhibit the SARS‐CoV‐2</td>
   </tr>
  </tbody>
 </table>
 <permissions>
  <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
 </permissions>
</table-wrap>
